Elevation of the tumor marker CA19-9 in a pancreatic cancer survivor with benign prostatic hyperplasia: A clinical case report.

肿瘤标志物 CA19 - 9 在患有良性前列腺增生的胰腺癌幸存者中的升高 ： 一个临床病例报告。

• 发表时间: 2024 Jun
• 来源期刊: Clin Case Rep
• DOI: 10.1002/ccr3.8929
• PMID: 38799519
• 文章类型: Case Reports
• 作者列表: Pendry SD,Singhal N,Neo EL,Foreman D,Winter JM

关键词: carbohydrate antigen 19‐9; pancreatic ductal adenocarcinoma; prostate; prostate specific antigen

Abstract

Serum carbohydrate antigen 19-9 (CA19-9) is used for recurrence surveillance in patients with resected pancreatic ductal adenocarcinoma (PDAC). This report describes the association of increasing CA19-9 in a male PDAC survivor with presence of prostatic hyperplasia. Unexplained elevation of CA19-9 in male PDAC survivors might be attributable to benign prostatic conditions.

摘要

血清碳水化合物抗原19-9（CA19-9）用于胰腺导管腺癌（PDAC）切除患者的复发监测。该报告描述了男性PDAC幸存者中CA19-9增加与前列腺增生的关系。男性PDAC幸存者中原因不明的CA19-9升高可能归因于良性前列腺疾病。